Allogene Therapeutics, Inc. (ALLO)

2.8550 -0.1850 (-6.09%) At close: 04:00PM EDT

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 232

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Arie S. Belldegrun F.A.C.S., M.D.	Co-Founder & Executive Chairman	649.1k	N/A	1949
Dr. David D. Chang M.D., Ph.D.	Co-Founder, President, CEO & Director	994.6k	N/A	1960
Mr. Joshua A. Kazam	Co-Founder & Director	260.5k	N/A	1977
Yinlin Chen	Senior Vice President of Finance	N/A	N/A	N/A
Mr. David M. Tanen J.D.	Secretary	N/A	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate governance

Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.